These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9636404)

  • 1. Liposomal tacrolimus: drug migration within blood compartments.
    McAlister VC
    Transplant Proc; 1998 Jun; 30(4):1000-1. PubMed ID: 9636404
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal tacrolimus and intestinal drug concentration.
    Dutta S; Mezei M; Lee TD; McAlister VC
    Transplant Proc; 1998 Sep; 30(6):2651-2. PubMed ID: 9745533
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity.
    McAlister VC; Keshavamurthy M; Lee TD
    Transplant Proc; 1999; 31(1-2):1110. PubMed ID: 10083495
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic characteristics of two types of liposomal FK 506.
    Yagura K; Nakajima Y; Ko S; Kanehiro H; Nakano H
    Transplant Proc; 1996 Jun; 28(3):1390-1. PubMed ID: 8658708
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies.
    Moffatt SD; McAlister V; Calne RY; Metcalfe SM
    Transplant Proc; 1999 Nov; 31(7):2754. PubMed ID: 10578277
    [No Abstract]   [Full Text] [Related]  

  • 6. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.
    Piekoszewski W; Chow FS; Jusko WJ
    Drug Metab Dispos; 1993; 21(4):690-8. PubMed ID: 7690698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of liposomal FK506 with FK506.
    Moffatt SD; McAlister V; Calne RY; Metcalfe S
    Transplant Proc; 1998 Dec; 30(8):4066-7. PubMed ID: 9865297
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate.
    Yoshimura N; Yura H; Hamashima T; Oka T; Takakura Y; Hadhida M
    Transplant Proc; 1998 Jun; 30(4):1029-30. PubMed ID: 9636415
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacokinetic benefits of newly developed liposome-incorporated FK506.
    Ko S; Nakajima Y; Kanehiro H; Yoshimura A; Nakano H
    Transplantation; 1994 Nov; 58(10):1142-4. PubMed ID: 7526494
    [No Abstract]   [Full Text] [Related]  

  • 10. Significance of newly developed liposomal FK 506 in canine liver transplantation.
    Ko S; Nakajima Y; Kanehiro H; Horikawa M; Yoshimura A; Taki J; Kido K; Aomatsu Y; Ueno M; Kin T
    Transplant Proc; 1995 Feb; 27(1):351-3. PubMed ID: 7533406
    [No Abstract]   [Full Text] [Related]  

  • 11. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.
    van Etten EW; ten Kate MT; Snijders SV; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1677-81. PubMed ID: 9661003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice.
    Oku N; Doi K; Namba Y; Okada S
    Int J Cancer; 1994 Aug; 58(3):415-9. PubMed ID: 8050822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal ischemia on plasma levels of FK 506 in rats.
    Sakr M; Zetti G; Gavaler J; Farghali H; Venkataramanan R; Carrieri G; Starzl T; Van Thiel D
    Transplant Proc; 1992 Feb; 24(1):425-8. PubMed ID: 1371625
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics, dosing principles, and blood level monitoring of FK506.
    Sewing KF
    Transplant Proc; 1994 Dec; 26(6):3267-9. PubMed ID: 7527962
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model.
    Moffatt SD; McAlister V; Calne RY; Metcalfe SM
    Transplantation; 1999 May; 67(9):1205-8. PubMed ID: 10342309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution.
    Choice E; Masin D; Bally MB; Meloche M; Madden TD
    Transplantation; 1995 Nov; 60(9):1006-11. PubMed ID: 7491673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients.
    Webb NJ; Stevenson PJ; Lewis MA; Postlethwaite RJ; Bradbury MG; Undre N
    Transplant Proc; 2002 Aug; 34(5):1948-50. PubMed ID: 12176639
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus.
    Alessiani M; Regazzi M; Abbiati F; Ferrari P; Molinaro M; Iacona I; Klersy C; Viezzoli A; Fayer F; Pileggi A; Zitelli E; Burroni B; Scandone M; Dionigi P; Zonta A
    Transplant Proc; 2000 Sep; 32(6):1214-5. PubMed ID: 10995915
    [No Abstract]   [Full Text] [Related]  

  • 19. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation.
    Ko S; Nakajima Y; Kanehiro H; Hisanaga M; Horikawa M; Aomatsu Y; Yagura K; Kin T; Ohyama T; Nishio K; Yamada T; Nakano H
    Transplant Proc; 1997; 29(1-2):529-31. PubMed ID: 9123117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion.
    Chow FS; Piekoszewski W; Jusko WJ
    Drug Metab Dispos; 1997 May; 25(5):610-6. PubMed ID: 9152601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.